Literature DB >> 1639232

Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.

B L Slomiany1, J Piotrowski, H Mojtahed, A Slomiany.   

Abstract

1. The effect of ebrotidine, a new antiulcer agent, on the activity of mucus degrading of protease and lipase enzymes elaborated by Helicobacter pylori was investigated. 2. In the absence of ebrotidine, the H. pylori protease caused extensive degradation of gastric mucus protein, while free fatty acids, glycerol mono-oleate and lysophosphatidylcholine were produced by the action of H. pylori lipase and phospholipase A enzymes. 3. Introduction of ebrotidine to the incubation system led to the reduction in the rate of mucus protein and lipid degradation. The rate of proteolysis inhibition was proportional to ebrotidine concentration up to 35 micrograms/ml at which point, a 57% reduction in mucus degradation was obtained, while the maximum inhibition of phospholipase A (96%) and lipase (93%) activities occurred at ebrotidine concentration of 60 micrograms/ml. 4. The results indicate that ebrotidine is capable of counteracting the mucolytic activity of H. pylori towards protein and lipid constituents of gastric mucus layer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639232     DOI: 10.1016/0306-3623(92)90010-h

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  3 in total

1.  Helicobacter pylori EstV: identification, cloning, and characterization of the first lipase isolated from an epsilon-proteobacterium.

Authors:  Cristian Ruiz; Serena Falcocchio; F I Javier Pastor; Luciano Saso; Pilar Diaz
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

Review 2.  Ebrotidine.

Authors:  S S Patel; M I Wilde
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

3.  Campylobacter jejuni gene cj0511 encodes a serine peptidase essential for colonisation.

Authors:  A V Karlyshev; G Thacker; M A Jones; M O Clements; B W Wren
Journal:  FEBS Open Bio       Date:  2014-05-09       Impact factor: 2.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.